{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:23:26Z","timestamp":1794248606722,"version":"4.9.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00335760"],"award-info":[{"award-number":["RS-2024-00335760"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00301914"],"award-info":[{"award-number":["RS-2023-00301914"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-25437447"],"award-info":[{"award-number":["RS-2025-25437447"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.isci.2026.117135","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T03:18:27Z","timestamp":1786418307000},"page":"117135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of FGFR signaling in SCLC and NSCLC: Current insights and therapeutic perspectives"],"prefix":"10.1016","volume":"29","author":[{"given":"Beom Chang","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyu Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee-Beom","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117135_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2026.117135_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.isci.2026.117135_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.117135_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/cancers17010082","article-title":"The complexity and significance of fibroblast growth factor (FGF) signaling for FGF-targeted cancer therapies","volume":"17","author":"Nguyen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117135_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.70016","article-title":"A Comprehensive Analysis of FGF\/FGFR Signaling Alteration in NSCLC: Implications in Prognosis and Microenvironment","volume":"16","author":"Huang","year":"2025","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.isci.2026.117135_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12943-024-02167-9","article-title":"Clinical advances and challenges in targeting FGF\/FGFR signaling in lung cancer","volume":"23","author":"Peng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.117135_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41416-025-03276-y","article-title":"Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer: Cellular and Molecular Biology","volume":"134","author":"Ernhofer","year":"2026","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.117135_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdiscip. Rev. Dev. Biol."},{"key":"10.1016\/j.isci.2026.117135_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.117135_bib11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","article-title":"FGF receptors: cancer biology and therapeutics","volume":"34","author":"Katoh","year":"2014","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.isci.2026.117135_bib12","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001451","article-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","volume":"2","author":"Weiss","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.117135_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jtho.2018.09.014","article-title":"Detection of known and novel FGFR fusions in non\u2013small cell lung cancer by comprehensive genomic profiling","volume":"14","author":"Qin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib16","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/jcmm.14763","article-title":"FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K\/Akt pathway via ENO1","volume":"24","author":"Chen","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.isci.2026.117135_bib17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/modpathol.2013.141","article-title":"Fibroblast growth factor receptor 1 (FGFR1) amplification is a potential therapeutic target in small-cell lung cancer","volume":"27","author":"Schultheis","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.isci.2026.117135_bib18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2021.04.005","article-title":"FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response","volume":"151","author":"Bogatyrova","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2026.117135_bib19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdv591","article-title":"A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10637-019-00783-7","article-title":"A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma","volume":"38","author":"van Brummelen","year":"2020","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.isci.2026.117135_bib21","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib22","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1200\/JCO.2019.37.15_suppl.4511","article-title":"FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis","volume":"37","author":"Siefker-Radtke","year":"2019","journal-title":"J Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib23","doi-asserted-by":"crossref","first-page":"9526","DOI":"10.3390\/ijms22179526","article-title":"Fibroblast growth factor inhibitors for treating locally advanced\/metastatic bladder urothelial carcinomas via dual targeting of tumor-specific oncogenic signaling and the tumor immune microenvironment","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117135_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejca.2016.03.068","article-title":"Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models","volume":"61","author":"Tsimafeyeu","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2026.117135_bib25","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s10637-023-01340-z","article-title":"A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer","volume":"41","author":"Tsimafeyeu","year":"2023","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.isci.2026.117135_bib26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.117135_bib27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3390\/ijms25020849","article-title":"Molecular targeting of the fibroblast growth factor receptor pathway across various cancers","volume":"25","author":"Shan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.117135_bib28","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib29","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.19.02630","article-title":"Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W","volume":"38","author":"Chae","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib30","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2022.08.016","article-title":"Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19\/18 phase II study","volume":"172","author":"Addeo","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.isci.2026.117135_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib33","doi-asserted-by":"crossref","first-page":"8515","DOI":"10.1200\/JCO.2024.42.16_suppl.8515","article-title":"Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial","volume":"42","author":"Schuler","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib34","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.str.2014.09.019","article-title":"Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4","volume":"22","author":"Tucker","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.isci.2026.117135_bib35","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1038\/ncomms8877","article-title":"Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase","volume":"6","author":"Klein","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117135_bib36","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib37","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1\u20134 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib38","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib39","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2026.117135_bib40","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1002\/onco.13552","article-title":"Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines","volume":"26","author":"Lacouture","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.isci.2026.117135_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41698-021-00208-w","article-title":"Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells","volume":"5","author":"Terp","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib42","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/JTO.0b013e31826aed28","article-title":"FGFR1 amplification in squamous cell carcinoma of the lung","volume":"7","author":"Heist","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib43","doi-asserted-by":"crossref","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2020.0120","article-title":"Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases","volume":"18","author":"Zhou","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.isci.2026.117135_bib44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5114\/aoms.2020.91284","article-title":"The association between fibroblast growth factor receptor 1 gene amplification and lung cancer: a meta-analysis","volume":"16","author":"Miao","year":"2020","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.isci.2026.117135_bib45","first-page":"1","article-title":"Practical Management of Adverse Events Associated With FGFR Inhibitors for Cholangiocarcinoma for the Advanced Practice Provider","volume":"1","author":"Schwartz","year":"2024","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib46","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1158\/1078-0432.CCR-23-2646","article-title":"Safety profile and adverse event management for Futibatinib, an irreversible FGFR1\u20134 inhibitor: pooled safety analysis of 469 patients","volume":"30","author":"Meric-Bernstam","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib47","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib48","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib49","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117135_bib50","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib51","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1080\/14656566.2023.2259802","article-title":"FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions","volume":"24","author":"Neureiter","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.isci.2026.117135_bib52","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1038\/s41388-019-0887-2","article-title":"Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer","volume":"38","author":"Raoof","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.117135_bib53","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/cells11193180","article-title":"Patient selection approaches in FGFR inhibitor trials\u2014many paths to the same end?","volume":"11","author":"Ellinghaus","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.isci.2026.117135_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO open"},{"key":"10.1016\/j.isci.2026.117135_bib55","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3390\/biom14121622","article-title":"Decoding FGF\/FGFR signaling: insights into biological functions and disease relevance","volume":"14","author":"Edirisinghe","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.isci.2026.117135_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174171","article-title":"Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer","volume":"133","author":"M\u00e4kinen","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.isci.2026.117135_bib57","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3390\/cells10061342","article-title":"Negative regulation of FGFR (fibroblast growth factor receptor) signaling","volume":"10","author":"Szybowska","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.isci.2026.117135_bib58","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1158\/1078-0432.CCR-25-2287","article-title":"FDA Approval Summary: Tarlatamab for the Treatment of Extensive Stage Small Cell Lung Cancer","volume":"32","author":"Liu","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib59","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib60","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/onco.13752","article-title":"FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer","volume":"26","author":"Mathieu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.isci.2026.117135_bib61","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib62","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1634\/theoncologist.2015-0221","article-title":"US Food and Drug Administration approval summary: ramucirumab for the treatment of metastatic non-small cell lung cancer following disease progression on or after platinum-based chemotherapy","volume":"20","author":"Larkins","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.isci.2026.117135_bib63","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib64","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/1078-0432.CCR-20-4338","article-title":"FDA approval summary: Nivolumab with ipilimumab and chemotherapy for metastatic non\u2013small cell lung cancer, A collaborative project orbis review","volume":"27","author":"Vellanki","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib65","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/oncolo\/oyae151","article-title":"FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations","volume":"29","author":"Mehta","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.isci.2026.117135_bib66","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib67","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib68","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117135_bib69","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non\u2013small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib70","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib71","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib72","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib73","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion\u2013positive non\u2013small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib74","article-title":"Successful treatment and retreatment with erdafitinib for a patient with FGFR3-TACC3 fusion squamous NSCLC: a case report","volume":"4","author":"Pham","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.isci.2026.117135_bib75","article-title":"NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 2.2025)","author":"Network","year":"2025","journal-title":"NCCN"},{"key":"10.1016\/j.isci.2026.117135_bib76","series-title":"Global Oncology Trends 2025: Outlook to 2030","author":"Science","year":"2025"},{"key":"10.1016\/j.isci.2026.117135_bib77","series-title":"NCI Annual Plan and Professional Judgment Budget for Fiscal Year 2025","author":"Institute","year":"2025"},{"key":"10.1016\/j.isci.2026.117135_bib78","series-title":"The National Cancer Plan","author":"Health","year":"2024"},{"key":"10.1016\/j.isci.2026.117135_bib79","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib80","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib81","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"De Langen","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117135_bib82","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib83","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jtho.2025.07.129","article-title":"Final analysis results and patient-reported outcomes from DESTINY-Lung02\u2014a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non\u2013small cell lung cancer","volume":"20","author":"J\u00e4nne","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib84","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib85","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117135_bib86","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8008","article-title":"Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304","volume":"43","author":"Rudin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib87","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117135_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.780650","article-title":"Fibroblast growth factor receptor 1-4 genetic aberrations as clinically relevant biomarkers in squamous cell lung cancer","volume":"12","author":"Moes-Sosnowska","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117135_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014117","article-title":"Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression","volume":"5","author":"Ware","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117135_bib90","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","article-title":"Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer","volume":"8","author":"Jacobsen","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117135_bib91","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lungcan.2019.08.011","article-title":"An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer","volume":"136","author":"Morgensztern","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.isci.2026.117135_bib92","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/1535-7163.MCT-23-0719","article-title":"A selective FGFR1\/2 PROTAC degrader with antitumor activity","volume":"23","author":"Kong","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2026.117135_bib93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12964-023-01203-3","article-title":"N-glycosylation acts as a switch for FGFR1 trafficking between the plasma membrane and nuclear envelope","volume":"21","author":"Gregorczyk","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.isci.2026.117135_bib94","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00018-023-04768-x","article-title":"Receptor clustering by a precise set of extracellular galectins initiates FGFR signaling","volume":"80","author":"Zukowska","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.isci.2026.117135_bib95","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cytogfr.2024.04.001","article-title":"Glycosylation of FGF\/FGFR: An underrated sweet code regulating cellular signaling programs","volume":"77","author":"G\u0119daj","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.isci.2026.117135_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128982","article-title":"Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform","volume":"75","author":"Guo","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.isci.2026.117135_bib97","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1039\/D3CS00344B","article-title":"Targeted protein degradation directly engaging lysosomes or proteasomes","volume":"53","author":"Kim","year":"2024","journal-title":"Chem. Soc. Rev."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226025137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226025137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:01:06Z","timestamp":1794247266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226025137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":97,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589004226025137"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117135","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of FGFR signaling in SCLC and NSCLC: Current insights and therapeutic perspectives","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117135","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117135"}}